Pre-earnings options volume in Capricor Therapeutics (CAPR) is normal with calls leading puts 20:1. Implied volatility suggests the market is anticipating a move near 10.6%, or 80c, after results are released. Median move over the past eight quarters is 8.8%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics appoints Binks as Chief Medical Officer
- Capricor Therapeutics, Inc. (CAPR) Q1 Earnings Cheat Sheet
- Capricor FDA panel meeting ‘not unexpected,’ says JonesResearch
- Capricor share weakness unwarranted, says H.C. Wainwright
- Capricor completes mid-cycle review with FDA for BLA for deramiocel